FDA approves LEO Pharma's Taclonex

COPENHAGEN, Denmark LEO Pharma has received approval from the Food and Drug Administration for Taclonex scalp topical solution.

Taclonex scalp is a topical suspension for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults aged 18 and older.

Warner Chilcott is LEO Pharma’s exclusive licensee of Taclonex and Dovonex products in the United States. Warner Chilcott expects to launch Taclonex scalp in the second half of 2008. As a result of the FDA approval of Taclonex scalp, Warner Chilcott will pay a milestone payment of $40 million to LEO Pharma in June 2008.

Taclonex had sales of over $67 million in 2007.